Table of contents
1. Immune System in Action
2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming
3. Immunotherapy for Melanoma
4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?
5. Landscape of Immunotherapy in Genitourinary Malignancies
6. Immuno-oncology for Gynecologic Malignancies
7. Immunotherapy for Neuro-oncology
8. Immunotherapy in Gastrointestinal Malignancies
9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!
10. CAR T-cells
11. Skin Reactions to Immune Checkpoint Inhibitors
12. Immunotherapy Mediated luminal Gastrointestinal toxicities
13. Hepatobiliary and Pancreatic Adverse Events
14. Pulmonary toxicities of immunotherapy
15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity
16. Renal Toxicity
17. Immune-Related Oral, Otologic and Ocular Adverse Events
18. Neurologic Toxicities of Immunotherapy
19. Cancer Imaging in Immunotherapy
About the Author: Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.